Longevity Health Holdings, Inc. (XAGE)
| Market Cap | 420.81K -79.7% |
| Revenue (ttm) | 1.69M +60.3% |
| Net Income | -6.83M |
| EPS | -3.46 |
| Shares Out | 2.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,891 |
| Open | 0.1699 |
| Previous Close | n/a |
| Day's Range | 0.1699 - 0.1700 |
| 52-Week Range | 0.1699 - 1.1400 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Longevity Health Holdings
Longevity Health Holdings, Inc., a bio-aesthetics company, focuses on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company utilizes Carmell Secretome and Elevai Exosomes to support skin and hair health. Its Carmell Secretome consists of growth factors, proteins, and peptides extracted from allogeneic human platelets; and Elevai Exosomes constains growth factors, cytokines, peptides, and other small molecules involved in the body’s natural healing process. The company also develops a microemulsion formula... [Read more]
Financial Performance
In 2025, Longevity Health Holdings's revenue was $1.91 million, an increase of 3701.44% compared to the previous year's $50,318. Losses were -$6.91 million, -33.40% less than in 2024.
Financial StatementsNews
Longevity Health Holdings Enters into Securities Purchase Agreement for Up to $625,000 in Gross Proceeds
Company draws initial $375,000 tranche from institutional investor Puritan Partners Company draws initial $375,000 tranche from institutional investor Puritan Partners
Longevity Health announces settlement in Puritan Partners litigation
Longevity Health (XAGE) Holdings has entered into a settlement agreement with Puritan Partners fully resolving the litigation captioned Puritan Partners LLC v. Carmell Regen Med Corporation, et al., I...
Longevity Health Holdings Announces Settlement of Litigation with Puritan Partners LLC
Settlement resolves litigation pending since November 2023 that had constrained the Company's access to capital and to pursue strategic opportunities
Longevity Health close strategic investment, appoints Ram Ajjarapu as CEO
Longevity Health (XAGE) Holdings’ Board of Directors has appointed Ram Ajjarapu as Chairman and CEO, effective as of March 16, 2026. In connection with his appointment, Mr. Ajjarapu made a…
Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
PITTSBURGH, March 17, 2026 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (OTCQB: XAGE) ("Longevity" or the "Company") announced that its Board of Directors has appointed Ram Ajjarapu as Chairman...
Why Is Longevity Health Stock (XAGE) Up 135% Today?
Longevity Health stock surged on Tuesday after the company posted details of a merger agreement.
Longevity Health Holdings Inc trading resumes
17:05 EDT Longevity Health (XAGE) Holdings Inc trading resumes
Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction
PITTSBURGH, July 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging (“Longevity”, the “Company”, “we”, “our”, or “us”),...
Longevity Health Holdings Inc trading halted, news pending
16:25 EDT Longevity Health (XAGE) Holdings Inc trading halted, news pending
Longevity Health extends cash runway into 1Q26
Longevity Health (XAGE) Holdings announced the sale of 479,621 shares of its common stock at an average price of $4.08 per share through its at-the-market equity offering facility. Gross proceeds…
Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale
Pittsburgh, PA, May 27, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE) (“XAGE,” the “Company,” “we” or “our”), a company dedicated to advancing human longevity and healthy agi...
Longevity announces continued Nasdaq listing to complete 20/20 BioLabs deal
Longevity Health (XAGE) announced that it has received a favorable decision from the Nasdaq Hearings Panel granting the company’s request to continue its listing on Nasdaq subject to the satisfaction…
Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs
PITTSBURGH, May 21, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE) (“XAGE,” the “Company,” “we,” “us,” or “our”), a company focused on extending human longevity and healthy ag...
Longevity Health reports unaudited Q1 revenue $663,000, up 8% year-over-year
Longevity Health (XAGE) announced the following business updates: Merger Agreement entered with 20/20 BioLabs: Merger Agreement executed on April 11, 2025, pursuant to which 20/20 is expected to conti...
Longevity Health Holdings Announces Business Updates
PITTSBURGH and GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on extending human longevity and healthy aging through technologica...
Longevity Health Holdings Inc trading halted, news pending
19:50 EDT Longevity Health (XAGE) Holdings Inc trading halted, news pending
Longevity Health announces 1-for-30 reverse stock split
Longevity Health (XAGE) Holdings has resolved to effect a reverse stock split of the Company’s common stock and has determined the ratio to be 1-for-30. The Company’s stockholders approved the…
Longevity Health Holdings, Inc. Announces Reverse Stock Split
PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc . (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today anno...
Longevity Health executes merger agreement with 20/20 Biolabs
Longevity Health (XAGE) Holdings announced the execution of a merger agreement with 20/20 BioLabs to combine the companies in an all-stock transaction. Following the closing of the Merger, the combine...